2 studies show benefits, risks of combo treatments with Herceptin

Patients with advanced breast cancer who received a combination of Herceptin and Tykerb survived almost five months longer than those who took only Tykerb, doctors reported at the San Antonio Breast Cancer Symposium. Another study presented at the conference suggests that despite the effectiveness of combining Herceptin and anthracyclines, patients had significantly more heart damage and cases of leukemia than a group taking Herceptin and nonanthracyclines.

View Full Article in:

Google · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY